Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Imidazoline-Binding Domains on Monoamine Oxidase B and Subpopulations of Enzyme

Rita Raddatz, Sandra L. Savic, Venkatesalu Bakthavachalam, John Lesnick, Jeffrey R. Jasper, Christopher R. McGrath, Angelo Parini and Stephen M. Lanier
Journal of Pharmacology and Experimental Therapeutics March 2000, 292 (3) 1135-1145;
Rita Raddatz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra L. Savic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkatesalu Bakthavachalam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Lesnick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey R. Jasper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher R. McGrath
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelo Parini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen M. Lanier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A series of phenoxy-substituted methylimidazoline derivatives were synthesized and used to define the ligand recognition properties of the imidazoline-binding domain (IBD) on monoamine oxidase (MAO)-B and its role in substrate processing. The rank order of potency for selected compounds in competitive binding studies with the imidazoline [3H]idazoxan was different from that in enzyme activity assays, suggesting that the IBD and the site involved in enzyme inhibition are distinct. IC50 values for inhibition of MAO-B activity by imidazoline/guanidinium ligands were one to two orders of magnitude greater than ligand concentrations that probably saturate the IBD, but were equal to theKd values of these ligands in competitive binding assays with the reversible MAO-B inhibitor [3H]Ro 19-6327. In addition, the degree of enzyme inhibition by these ligands was similar in platelet and liver, tissues exhibiting 10-fold differences in the amount of the IBD-accessible enzyme subpopulation. These data suggested that the inhibitory effect of these compounds on MAO-B activity involved a secondary interaction with the enzyme domain recognizing the inhibitor Ro 19-6327 and does not involve interaction with the IBD. Subsequent radioligand-binding studies indicated that human liver MAO-B actually existed as two distinct populations that differed in the accessibility of their IBD. The relatively small amounts of MAO-B possessing an accessible IBD (∼5% in human liver) precludes determination of the functional consequences of ligand binding to the IBD. This subpopulation of MAO-B may be selectively regulated or generated in different individuals or tissues and targeted by pharmacologically active compounds in a cell type-specific manner.

Footnotes

  • Send reprint requests to: Stephen M. Lanier, Ph.D., Department of Pharmacology, Medical University of South Carolina, 171 Ashley Ave., Charleston, SC 29425-2251. E-mail:laniersm{at}musc.edu

  • ↵1 This work was supported by National Institutes of Health Grants NS35875-01 (to S.M.L.), GMR43 GM54457 (to V.B.), T32-HL-7260 (to R.R.), and F32 NS10332 (to R.R.). The Brain Tissue Resource Center is supported in part by Mental Health/Neuroscience 31862. The National Neurological Research Specimen Bank is supported by National Institute of Neurological Disorders and Stroke/National Institute of Mental Health, National Multiple Sclerosis Society, Hereditary Disease Foundation, Comprehensive Epilepsy Program, Tourette Syndrome Association, Dystonia Medical Research Foundation, and Veteran's Health Services and Research Administration.

  • ↵2 The imidazoline BU224 and the guanidinium guanabenz exhibit Ki values of 1 to 10 nM for the IBD on MAO-B as determined in radioligand-binding studies with [3H]idazoxan or photoaffinity labeling with [125I]AZIPI.

  • Abbreviations:
    MAO
    monoamine oxidase
    IBD
    imidazoline-binding domain
    [125I]AZIPI
    2-[3-azido-4[125I]iodophenoxy] methyl imidazoline
    2BFI
    2-(2-benzofuranyl)-2-imidazoline
    Ro 19-6327
    N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide
    Ro 16-6491
    N-(2-aminoethyl)-p-chlorobenzamide
    BU224
    2-(4,5-dihydroimidaz-2-yl)-quinoline
    BOC
    N-t-butoxycarbonyl
    MS
    mass spectrometry
    HEK
    human embryonic kidney
    α2-AR
    α2-adrenoceptor
    • Received June 25, 1999.
    • Accepted November 13, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 292 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 292, Issue 3
1 Mar 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Imidazoline-Binding Domains on Monoamine Oxidase B and Subpopulations of Enzyme
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Imidazoline-Binding Domains on Monoamine Oxidase B and Subpopulations of Enzyme

Rita Raddatz, Sandra L. Savic, Venkatesalu Bakthavachalam, John Lesnick, Jeffrey R. Jasper, Christopher R. McGrath, Angelo Parini and Stephen M. Lanier
Journal of Pharmacology and Experimental Therapeutics March 1, 2000, 292 (3) 1135-1145;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNEUROPHARMACOLOGY

Imidazoline-Binding Domains on Monoamine Oxidase B and Subpopulations of Enzyme

Rita Raddatz, Sandra L. Savic, Venkatesalu Bakthavachalam, John Lesnick, Jeffrey R. Jasper, Christopher R. McGrath, Angelo Parini and Stephen M. Lanier
Journal of Pharmacology and Experimental Therapeutics March 1, 2000, 292 (3) 1135-1145;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P-Glycoprotein Apical Efflux Ratio for Compound Optimization
  • Pharmacology of Carbamate Insecticides at Melatonin Receptors
  • Metalloporphyrins modify disease outcomes in parkinsonism
Show more Neuropharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics